Metastasis is the primary cause of death in renal cell carcinoma (RCC). Loss of cell-to-cell adhesion, including tight junctions (TJs) is the initial step in the process of metastasis. Claudin-7 (CLDN7) is a major component of TJs. However, the clinical significance and its regulation of kidney tumorigenesis remain poorly understood.
INTRODUCTION AND OBJECTIVES:
Metastasis is the primary cause of death in renal cell carcinoma (RCC). Loss of cell-to-cell adhesion, including tight junctions (TJs) is the initial step in the process of metastasis. Claudin-7 (CLDN7) is a major component of TJs. However, the clinical significance and its regulation of kidney tumorigenesis remain poorly understood.
METHODS: Total 120 fresh ccRCC specimen and 144 primary RCC and adjacent non-malignant renal paraffin specimen were obtained from Peking University First Hospital. Expression of CLDN7 in ccRCC were determined by bioinformatic data mining, qRT-PCR, Western blot and immunostaining. The clinical significance of CLDN7 expression and promoter methylation status was analyzed in ccRCC patients. The methylation specific-PCR, bisulfite genomic sequencing and demethylation analysis of CLDN7 were performed in ccRCC. Biological functions of lentivirus-mediated CLDN7 overexpression on ccRCC cells proliferation, migration and invasion were investigated. Mice experiments were performed to confirm effects of CLDN7 on tumor growth and metastasis in vivo. Molecular mechanism of CLDN7 function was investigated by gene-set enrichment analysis (GSEA) and high-throughput cDNA sequencing (RNA-Seq) and confirmed by qRT-PCR, western blot and immunostaining in vitro and in vivo.
RESULTS: CLDN7 was frequently downregulated via hypermethylation of its promoter in ccRCC. CLDN7 can help predict aggressive tumor status and poor prognosis in ccRCC patients. Hypermethylation of CLDN7 promoter was related to advanced ccRCC and poor prognosis. Moreover, overexpression of CLDN7 induced cell apoptosis, suppressed proliferation, migration and invasion abilities of ccRCC cells both in vitro and in vivo. In addition, GSEA and RNA-Seq results showed high expression of CLDN7 had negative effect in cancer-associated signaling pathways and (epithelial-mesenchymal transition) EMT-related pathways, and results were validated by qRT-PCR, Western blot and immunostaining.
CONCLUSIONS: We have demonstrated a previously undescribed role of CLDN7 as a ccRCC suppressor and suggest that loss of CLDN7 potentiates EMT and tumor progression. CLDN7 may serve as a functional tumor suppressor in tumor progression and a potential biomarker and target in patients with ccRCC. RESULTS: In the present study, we found that expression of ERb, but not ERa, increases with tumor stage and grade. We also observed that modification of ERb signals using estrogens/anti-estrogens, shRNA knockdown of ERb and ectopic expression of ERb could affect RCC cell proliferation, migration and invasion. TCGA database analysis showed that the increased ERb is associated with a worse survival for RCC patients. Mechanism analysis revealed that ERb can promote RCC cell invasion via increasing transforming growth factor b1 (TGF-b1)/SMAD3 signals, and interrupting TGF-b 1/SMAD3 signals with a TGFb R1 inhibitor can reverse/block ERb -increased RCC cell migration.
CONCLUSIONS: ERb can promote RCC cell invasion via upregulating TGF-b1)/SMAD3 signals. Compared to Faslodex and PHTPP, tamoxifen is not an effective anti-estrogen for RCC treatment. Importantly, preclinical analyses using in vivo mouse models of RCC revealed that targeting of this newly identified ERb/TGF-b1/SMAD3 pathway with either the FDA-approved antiestrogen ICI182,780 (Faslodex) or a selective ERb antagonist PHTPP can significantly reduce RCC tumor growth and invasion, which may be suitable as the basis for novel therapies to more effectively suppress metastatic RCC.
Source of Funding: Urology research fund, and the George Whipple Professorship Endowment of UR Medical Center of US, and National Natural Science Foundation of China.
MP16-05 LOWERING MRNA EXPRESSION OF PLEKHO1 INHIBITS TUMOR GROWTH OF RCC CELLS IN VITRO AND IN VIVO, POTENTIALLY THROUGH MODULATING THE HIPPO AND MAPK/JNK SIGNALLING PATHWAYS
Yu Zeng*, Zi Yu, Shui Fu, Gejun Zhang, Chengcheng Lv, Qingzhuo Dong, Chuize Kong, Cheng Fu, Shenyang, China, People's Republic of INTRODUCTION AND OBJECTIVES: Renal cell carcinoma (RCC) is the most common type of kidney cancer word widely. Although target therapy and checkpoint immunotherapy improve the survival of metastatic RCC, a large number of patients are still incurable.
METHODS: The raw RNA-sequencing data of RCC were download from the Cancer Genome Atlas (TCGA) database and exported by using R-project. A high-content cell viability assay was used to screen genes those are potentially regulating cell proliferation after downregulating the mRNA expressions of each gene by shRNA. RT-PCR was conducted to detect the mRNA expression of pleckstrin homology domain containing O1 (PLEKHO1) gene in 30 paired localized tumor and para-tumor kidney tissue samples. The effects of lowering the expression of PLEKHO1 were assessed by CCK-8 assay, Celigo assay, flow cytometry and transwell assay, separately. Additionally, xenograft tumor models were established in nude mice to investigate the function of PLEKHO1 in vivo. Gene expression microarray and co-expression analysis followed by Western blot were further conducted to explore the involvement of PLEKHO1 in signalling pathways.
RESULTS: Sixteen genes were identified to be consistently highly expressed in ccRCC tissue compared with the matched paratumor tissue in TCGA data set, while downregulation of only two of those significantly inhibited the viability of RCC cells. Among two genes, PLEKHO1 was unknown in its relevance to RCC and its expression level was shown to be associated with prognosis of RCC in the TCGA data set. Next, upregulation of PLEKHO1 mRNA was confirmed in RCC tissue samples. Reducing the expression of PLEKHO1 by specific siRNAs significantly inhibited cell viability and cell migration, and facilitated apoptosis in 786-0 and Caki-1 cells. In addition, knocking-down the expression of PLEKHO1 greatly impeded xenografted tumor's growth in nude mice. Finally, signalling pathways exploring by microarray analysis indicated that PLEKHO1-knockdown decreased the expressions of TAZ and CTGF, which are two key factors in HIPPO signalling pathway, and simultaneously reduced the expressions of p-JNK and c-Jun, which are two key factors in the JNK signalling pathway, in 786-O cells.
CONCLUSIONS: These results suggest that the aberrant expression of PLEKHO1 in RCC may contribute to tumor growth, and therefore the potential of PLEKHO1 as a therapeutic target needs to be further studied.
Source of Funding: National Natural Science Foundation of China (grant nos. 81372766 and 81572532), and the Liaoning "Climbing" scholarship.
MP16-06 EXPLOITING NOVEL THERAPEUTIC TARGETS TO BLOCK METASTASIS OF CLEAR CELL RENAL CELL CARCINOMA (RCC)
Jan Rudzinski*, Natasha Govindasamy, Konstantin Stoletov, Adrian Fairey, John Lewis, Edmonton, Canada INTRODUCTION AND OBJECTIVES: Metastatic RCC is incurable, and the current therapeutic paradigm is centered around controlling the disease burden to prolong overall survival. We conducted a whole human genome short hairpin RNA (shRNA) screen on human squamous cell carcinoma (Hep3) cells to identify a panel of novel functional genes that are required for productive cell motility and successful metastatic dissemination. One such novel protein target encodes for chromosome 14 open reading frame 142 (C14orf42), which has been demonstrated to be up regulated in metastatic clear cell RCC. The objective of our study was to characterize the impact of C14orf142 on clear cell RCC in vitro motility, invasion, and in vivo vascular extravasation.
METHODS: Benign proximal convoluted tubule cells (PCT) and clear cell RCC cell lines 786-0 (derived from renal tissue) were obtained from American Type Culture Collection (ATCC). Targeted genomic editing to knockout (KO) C14orf142 was achieved with CRISPR-Cas9 system. Successful protein knockdown was validated using western blot analysis. To measure impact of gene KO on in vitro invasion we conducted the FITC-gelatin degradation assay. To measure the combined effect of invasion and productive cell migration in vitro we utilized the modified Boyden chamber assay coated with 0.1% gelatin. To study cancer cell vascular extravasation in vivo, 786-0 cells were injected IV into fertilized avian embryos. For statistical analysis, t-test was used to evaluate differences between groups with p value of 0.05 accepted as statistically significant.
RESULTS: The baseline expression of C14orf142 was significantly higher in 786-0 (1.078AUDAE0.11) compared to PCT(0.12AUDAE0.04) (p 0.05). The CRISPR-Cas9 targeted genomic editing resulted in generation of 786-0 clones with complete KO of C14orf142. The FITC-gelatin degradation assay demonstrated significant difference in gelatin degradation between 786-0 scramble
